Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin

Journal of Clinical Oncology

Volumn 15, Issue 7, 1997, Pages 2553-2558

  Xiao, Han ^a   Mazumdar, Madhu ^a   Bajorin, Dean F ^a   Sarosdy, Michael ^a   Vlamis, Vaia ^a   Spicer, Jacquelyn ^a   Ferrara, Jay ^a   Bosl, George J ^a   Motzer, Robert J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE;

ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; GERM CELL TUMOR; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEMINOMA; TESTIS TUMOR; TREATMENT OUTCOME;

EID: 0030757467     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.7.2553     Document Type: Article

References (16)

1. Bosl GJ, Gluckman R, Geller NL, et al: VAB-6: An effective chemotherapy regimen for patients with germ-cell tumors. J Clin Oncol 4:1493-1499, 1986
2. Einhorn LH, Williams SD, Troner M, et al: The role of maintenance therapy in disseminated testicular cancer. N Engl J Med 305:727-731, 1981
3. Williams SD, Birch R, Einhorn LH, et al: Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316:1435-1440, 1987
4. Vogelzang NJ, Bosl GJ, Johnson K, et al: Raynaud's phenomenon: A common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med 95:288-292, 1981
5. Bajorin D, Katz A, Chan E, et al: Comparison of criteria for assigning germ cell tumor patients to "good risk" and "poor risk" studies. J Clin Oncol 6:786-792, 1988
6. Bosl GJ, Geller NL, Cirrincione C, et al: Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res 43:3403-3407, 1983
7. Motzer RJ, Bosl GJ, Geller NL, et al: Advanced seminoma: The role of chemotherapy and adjunctive surgery. Ann Intern Med 108:513-518, 1988
8. Bosl GJ, Geller NL, Bajorin D, et al: A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol 6:1231-1238, 1988
9. Bajorin DF, Sarosdy MF, Pfister DG, et al: Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: A multiinstitutional study. J Clin Oncol 11:598-606, 1993
10. Mead GM: International consensus prognostic classification for metastatic germ cell tumors treated with platinum based chemotherapy: Final report of the International Germ Cell Cancer Collaborative Group (IGCCCG). Proc Am Soc Clin Oncol 14:235, 1996 (abstr)
11. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
12. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
13. Bajorin DF, Motzer RJ, Rodriquez E, et al: Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy. J Natl Cancer Inst 85:60-62, 1993
14. Loehrer P, Johnson D, Elson P, et al: Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: An Eastern Cooperative Oncology Group trial. J Clin Oncol 13:470-476, 1995
15. Stoter G. Kaye S, ten Bokkel HWW, et al: Cisplatin (p) and VP-16 (E) +/- bleomycin (B) (BEP vs EP) in good risk patients with disseminated non-seminomatous testicular cancer: A randomized EORTC GU group study. Proc Am Soc Clin Oncol 6:110, 1987 (abstr)
16. Einhorn LH, Williams SD, Loehrer PJ, et al: Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: A Southeastern Cancer Study Group protocol. J Clin Oncol 7:387-391, 1989